These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34244855)

  • 21. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
    Rocca A; Farolfi A; Bravaccini S; Schirone A; Amadori D
    Expert Opin Pharmacother; 2014 Feb; 15(3):407-20. PubMed ID: 24369047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
    Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
    Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.
    Pandey K; Lee E; Park N; Hur J; Cho YB; Katuwal NB; Kim SK; Lee SA; Kim I; An HJ; Hwang S; Moon YW
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33504001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
    Finn RS; Dering J; Conklin D; Kalous O; Cohen DJ; Desai AJ; Ginther C; Atefi M; Chen I; Fowst C; Los G; Slamon DJ
    Breast Cancer Res; 2009; 11(5):R77. PubMed ID: 19874578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
    Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
    Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
    Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L
    Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
    Soosainathan A; Iravani M; El-Botty R; Alexander J; Sourd L; Morisset L; Painsec P; Orha R; Nikitorowicz-Buniak J; Pancholi S; Haider S; Dowsett M; Marangoni E; Martin LA; Isacke CM
    Cancer Res; 2024 Jan; 84(1):17-25. PubMed ID: 37801608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
    Iida M; Toyosawa D; Nakamura M; Tsuboi K; Tokuda E; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2020 Sep; 27(5):963-972. PubMed ID: 32297248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
    AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
    Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.
    Lorman-Carbó N; Martínez-Sáez O; Fernandez-Martinez A; Galván P; Chic N; Garcia-Fructuoso I; Rodríguez A; Gómez-Bravo R; Schettini F; Blasco P; Castillo O; González-Farré B; Adamo B; Vidal M; Muñoz M; Perou CM; Malumbres M; Gavilá J; Pascual T; Prat A; Brasó-Maristany F
    Sci Rep; 2024 Jul; 14(1):16030. PubMed ID: 38992220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
    De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
    Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
    Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
    Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
    Ma CX; Gao F; Luo J; Northfelt DW; Goetz M; Forero A; Hoog J; Naughton M; Ademuyiwa F; Suresh R; Anderson KS; Margenthaler J; Aft R; Hobday T; Moynihan T; Gillanders W; Cyr A; Eberlein TJ; Hieken T; Krontiras H; Guo Z; Lee MV; Spies NC; Skidmore ZL; Griffith OL; Griffith M; Thomas S; Bumb C; Vij K; Bartlett CH; Koehler M; Al-Kateb H; Sanati S; Ellis MJ
    Clin Cancer Res; 2017 Aug; 23(15):4055-4065. PubMed ID: 28270497
    [No Abstract]   [Full Text] [Related]  

  • 39. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer.
    Kong T; Xue Y; Cencic R; Zhu X; Monast A; Fu Z; Pilon V; Sangwan V; Guiot MC; Foulkes WD; Porco JA; Park M; Pelletier J; Huang S
    Mol Cancer Ther; 2019 Nov; 18(11):2158-2170. PubMed ID: 31395685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.